Abstract | BACKGROUND: METHODS: RESULTS: There was no significant difference between the ablation and drug-therapy groups in the cumulative burden of atrial fibrillation (90th percentile of arrhythmia burden, 13% and 19%, respectively; P=0.10) or the burden at 3, 6, 12, or 18 months. At 24 months, the burden of atrial fibrillation was significantly lower in the ablation group than in the drug-therapy group (90th percentile, 9% vs. 18%; P=0.007), and more patients in the ablation group were free from any atrial fibrillation (85% vs. 71%, P=0.004) and from symptomatic atrial fibrillation (93% vs. 84%, P=0.01). One death in the ablation group was due to a procedure-related stroke; there were three cases of cardiac tamponade in the ablation group. In the drug-therapy group, 54 patients (36%) underwent supplementary ablation. CONCLUSIONS:
|
Authors | Jens Cosedis Nielsen, Arne Johannessen, Pekka Raatikainen, Gerhard Hindricks, Håkan Walfridsson, Ole Kongstad, Steen Pehrson, Anders Englund, Juha Hartikainen, Leif Spange Mortensen, Peter Steen Hansen |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 367
Issue 17
Pg. 1587-95
(Oct 25 2012)
ISSN: 1533-4406 [Electronic] United States |
PMID | 23094720
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Arrhythmia Agents
- Propafenone
- Flecainide
|
Topics |
- Aged
- Anti-Arrhythmia Agents
(adverse effects, therapeutic use)
- Atrial Fibrillation
(diagnosis, drug therapy, surgery)
- Atrial Flutter
(diagnosis)
- Catheter Ablation
(adverse effects)
- Cost of Illness
- Electrocardiography, Ambulatory
- Female
- Flecainide
(adverse effects, therapeutic use)
- Follow-Up Studies
- Humans
- Intention to Treat Analysis
- Male
- Middle Aged
- Propafenone
(adverse effects, therapeutic use)
- Quality of Life
- Statistics, Nonparametric
- Treatment Outcome
|